Corsair Pharma Announces $23 Million Series B Financing to Advance Clinical Trials in Pulmonary Arterial Hypertension

Corsair Pharma, Inc. announced the closing of its $23M Series B financing led by New Rhein Healthcare Investors. Proceeds from the financing will support the clinical advancement of Corsair’s lead product candidate, a prodrug of treprostinil delivered in a proprietary transdermal patch to treat Pulmonary Arterial Hypertension.